FDA Alerts and Recalls
Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg and Exotique Foods' Momchipz veggie chips were the material August 24 notices. Consumers should follow the return, disposal or clinician instructions in the specific notices and not use affected product.
What changed
FDA's index added Vitruvias Therapeutics Thyroid Tablets, USP 30 mg and Momchipz veggie chips on August 24, 2026. Exact published lot identifiers, expiration dates, geographic scope and confirmed-harm counts were not available in the indexed extract and therefore are not invented.
Why it matters
Superpotent thyroid medication can cause serious dosing harm, while undeclared wheat threatens consumers with wheat allergy or celiac disease.
What to watch next
Product-specific FDA pages and Enforcement Report entries for identifiers, classification and status.
What we know
- Vitruvias Therapeutics recalled one lot of Thyroid Tablets, USP 30 mg nationwide for potential superpotency; FDA listed the notice on August 24 after an August 21 company announcement.
- Momchipz broccoli-floret and cauliflower veggie chips were recalled for undeclared wheat; FDA listed the notice on August 24.
- Both were FDA-posted company announcements; FDA posting does not independently endorse every company statement.
- Final recall class, confirmed harm counts and termination status were not reported in the available listings.
Material unknowns
- Final recall class
- Lot and expiration identifiers not visible in the retrieved index
- Confirmed harm counts
- Recall effectiveness
U.S. strategic assessment
High interestFDA notification supports immediate risk reduction, but public listings must not be confused with completed FDA investigations or final classifications.
Objectives
- Remove affected products
- Inform clinicians and consumers
- Complete classification and effectiveness checks
Strategy
- FDA publication of company announcements
- Enforcement Report classification
- MedWatch adverse-event reporting
Outcomes
- Two notices posted August 24
- No confirmed illness, injury or death count was reported in the available notices
Risks
- Medication dosing injury
- Allergic reaction
- Incomplete consumer reach
- Unreported recall effectiveness
Sources
01Current notice listing
Classification and status control
Drug-specific scan
MedWatch and device scan pathway
Independent agency-context check